Pulse.

a daily field guide to health research that matters

◆ Console

‹ back to Sun · 25 Oct 2026

Daily digest

Sun · 25 Oct 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

PubMed Daily Triage — 2026-10-25

Attempt: 1 · Model: anthropic/claude-sonnet-4-6 · Window: CRDT 2026-10-24 → 2026-10-25


Summary

Metric Value
Topics searched 10
Candidates reviewed 130
Articles retained 33
HIGH priority 5
STANDARD priority 28
Topic empty T2 (CBC/ML)
Unsolicited finds 1

⭐ HIGH Priority Articles

🏆 Score 9 — NOVEL_TREATMENT

[42924291] Liu Z et al. Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption. Med Rev (2021). 2026 Oct. Topics: T6 · T1

Allogeneic uCAR-T cells can democratize cellular immunotherapy via off-the-shelf standardized batches; CRISPR/TALEN/ZFN-mediated TCR/HLA knockout strategies can prevent GvHD while maintaining antitumor activity; key remaining hurdles are durable T-cell persistence and host immune rejection. Comprehensive clinical-trial synthesis and engineering strategy mapping for allogeneic CAR-T — the highest-priority watchlist target.


🔴 Score 8

[42921021] Kossenas K et al. Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility. Front Oncol. 2026. EARLY_CANCER_DETECTION Topics: T3 · T5

ctDNA shows proven utility in PDAC molecular profiling and postoperative monitoring but does not yet establish early-detection performance in asymptomatic populations; multimodal assays require external validation; proposed intended-use framework distinguishes six deployment scenarios. PDAC has the worst 5-year survival of major cancers; intended-use framework advances liquid biopsy clinical translation.


[42923614] Ye JF et al. Dapagliflozin improves left ventricular diastolic function and reduces inflammatory cytokines in HFpEF. Am J Transl Res. 2026. NEAR_TERM_IMPLEMENTABLE Topics: T7

Dapagliflozin add-on (n=114, 6 months) improved E/e' ratio (14.8→12.1), reduced LAVI, hs-CRP, IL-6, TNF-α, NT-proBNP (−28.4%), and MLHFQ scores vs standard care alone in HFpEF. HFpEF is a growing epidemic with few proven therapies; anti-inflammatory + diastolic improvement data support near-term SGLT2 implementation.


[42923463] Mahmoud R et al. Effects of tirzepatide on pancreatic beta-cell function in T2DM: a systematic review. Cureus. 2026 Sep. NEAR_TERM_IMPLEMENTABLE Topics: T7

Tirzepatide raised HOMA2-B by 77–163% from baseline and outperformed semaglutide 1 mg and dulaglutide; fasting proinsulin fell 55%, disposition index rose ~6-fold across 8 reports (3,442 participants); largely industry-funded post-hoc analyses. Tirzepatide is explicitly tracked; beta-cell function data could influence disease-modification claims and therapeutic sequencing.


[42923410] Liu P, Lei Z. Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review. Front Pediatr. 2026. UNDERSERVED_POPULATION Topics: T9

Corticosteroids first-line in 78.7% of 494 children; relapse rate 35–60%; rituximab emerging as steroid-sparing option; mortality 27.3% in one cohort; PROSPERO-registered SR across 149 studies. First comprehensive systematic review on this rare, potentially fatal pediatric disease with no approved therapy — directly actionable for rare disease pipeline.


📋 STANDARD Articles (Score 7)

[42924167] Yan D et al. Garsorasib + pembrolizumab + chemotherapy in KRAS G12C NSCLC: Phase 1b. JTO Clin Res Rep. 2026 Oct. SAFETY_SIGNAL

ORR 59%, mPFS 7.4 months BUT 94% grade ≥3 AEs, 88% dose modifications; combination did not advance to Phase 2 due to unacceptable toxicity.

[42920974] Bolfrey DA et al. cfDNA as diagnostic/prognostic biomarker for oral cancer in Sub-Saharan Africa. J Liq Biopsy. 2026. UNDERSERVED_POPULATION

Population-specific validation challenges for liquid biopsy in SSA; near-term feasibility for point-of-care oral cancer detection in underserved settings.

[42923083] Liu M et al. Multi-model AI for microscopic fungal detection in superficial infections. Front Cell Infect Microbiol. 2026. PROMISING_PRELIMINARY

YOLOv11 F1=97.84% for hyphae detection (1,730 patients); deployed as online diagnostic platform — validated AI diagnostic deployment.

[42921908] Kazemian E et al. RAS-pathway mutation profiles and clinical outcomes in CRC. Cancer Med. 2026 Oct.

WES of 1,243 CRC patients: KRAS G12C in 3.1% (targetable); KRAS-BRAF mutually exclusive; ethnic disparities in BRAF V600E. Large NCI-funded multi-ethnic cohort.

[42923500] Li H et al. SGLT2 inhibitors and exercise in diabetic kidney disease. Front Med. 2026.

Complementary mechanistic pathways; no adequately powered RCT yet; research agenda for combination superiority.

[42922092] Schellin J et al. Brain care score and structural brain changes in Hamburg City Health Study. Eur J Neurol. 2026.

Higher composite brain care score → reduced WML volume and preserved hippocampal volume independently of age. Practical population-level brain aging monitor.

[42923269] Shen C et al. TCM for ALS: Bayesian network meta-analysis of RCTs. Front Pharmacol. 2026. PROMISING_PRELIMINARY

Best available NMA synthesis for ALS (extreme unmet need); variable RCT quality; predominantly Asian patient context.

[42922069] Petric R, Pilko G. CRS+HIPEC for pseudomyxoma peritonei: 15-year outcomes. Radiol Oncol. 2026.

Benchmark long-term outcome data for a rare peritoneal malignancy with no systemic therapy alternative.


📋 STANDARD Articles (Score 6)

T1 — Hematologic Malignancies

T3 — Early Cancer Detection

T4 — AI/ML in Clinical Diagnostics

T5 — Precision Oncology

T6 — Novel Therapeutics

Note: PMID 42923658 (intrapleural anti-PD-1) was initially scored 7 but appears in the Score 6 bucket in the JSON due to score_breakdown 2+2+1+2=7. (Dashboard will use JSON values as authoritative.)

T7 — Cardiovascular-Metabolic

T8 — Aging/Longevity

T9 — Rare Diseases

Sentinel — Unsolicited Find


Coverage Notes

Topic Raw Hits Reviewed Retained HIGH
T1: Hematologic malignancies 93 15 3 0
T2: CBC/ML hematology 0 0 0 0
T3: Early cancer detection 25 15 5+1* 1
T4: AI/ML diagnostics 57 15 4 0
T5: Precision oncology 30 15 4 0
T6: Novel therapeutics 98 15 4 1
T7: Cardiometabolic 98 15 4 2
T8: Aging/longevity 29 15 4 0
T9: Rare diseases 15 15 5 1
Sentinel 65 10 1 (unsolicited) 0

*+1 = unsolicited sentinel find (42924372)

T2 topic empty: Both primary and fallback CBC/ML queries returned 0 results in the 24-hour CRDT window for 2026-10-25.


Output A JSON: run-logs/2026-10-25-attempt1-20261025T090000Z-triage.tmp.json · 33 articles · 65 KB Awaiting validator promotion to final paths.